Lupin Limited has informed the Exchange regarding a press release dated March 31, 2026, titled "Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Sugammadex Injection, available in 200 mg/2 mL and 500 mg/5 mL single-dose vial strengths. The product is a generic version of Merck's Bridion Injection, used to reverse neuromuscular blockade caused by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery. As a tentative approval, Lupin is currently not able to launch the product in the U.S. market due to ongoing patent or exclusivity protections on the reference drug, but can do so once those barriers expire. This strengthens Lupin's complex generics portfolio in the U.S., a key revenue market for the company.
Positive for shareholders — adds to Lupin's U.S. pipeline of complex generics, with future revenue potential once market entry is allowed. No immediate financial impact expected, but it signals ongoing product momentum in a lucrative therapy area.